Biomarkers Consortium - Use of Targeted Multiplex Proteomic Strategies to Identify Plasma-Based Biomarkers in Alzheimer’s Disease

Overview

The lack of tools for early diagnosis and disease progression in Alzheimer’s disease (AD) continues to be a major hurdle in AD drug development. The identification and validation of cost-effective, non-invasive tools to identify AD during early disease stages and to monitor treatment effects in mild-moderate AD patients could revolutionize current clinical trial practice. Early treatment would also ensure intervention occurs prior to irreversible neuropathology. The Biomarkers Consortium’s Targeted Plasma-Based Biomarkers in Alzheimer’s Disease (AD), completed in Q3Y12, was the first part of a multi-phased effort utilizing samples from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to validate multiplex panels in both plasma and cerebrospinal fluid (CSF), for the identification of viable plasma-based biomarkers of AD, for diagnosis and disease progression.

Partners

  • NIH Office of the Director (OD)
  • Pfizer
  • University of Pennsylvania

Contact

  • Wesley Horton, M.S., Scientific Project Manager, Neuroscience, whorton@fnih.org

Goals

  • To utilize a new multiplex immunoassay panel as a tool to diagnose and monitor disease progression in the ADNI cohort using baseline plasma samples.
  • The ultimate goal would be to qualify the multiplexed panel for use in clinical trials (this would not be done via this project but at later stages).

Results & Accomplishments

Results confirm independent studies reporting increased levels of NT-proBNP in AD. MCI subjects that progressed to dementia within a 48 month follow-up period showed decreased levels of ApoE in comparison to MCI subjects that had not yet progressed. A biochemical phenotype is associated with the ApoE genotype.

Scientific Publications